Abstract:The search for new metal-based anticancer drug candidates is a fundamental task in medicinal inorganic chemistry. In this work, we assessed the potential of two new Ru( II )–phosphine–mercapto complexes as potential anticancer agents. The complexes, with the formula [Ru(bipy)(dppen)(Lx)]PF 6 [( 1 ), HL1 = 2-mercapto–pyridine and ( 2 ), HL2 = 2-mercapto–pyrimidine, bipy = 2,2′-bipyridine, dppen = cis -1,2-bis(diphenylphosphino)-ethylene] were synthesized and characterized by nuclear magnetic resonance (NMR) [ 1 H, 31 P( 1 H), and 13 C], high resolution mass spectrometry (HR-MS), cyclic voltammetry, infrared and UV-Vis spectroscopies. Complex 2 was obtained as a mixture of two isomers, 2a and 2b , respectively. The composition of these metal complexes was confirmed by elemental analysis and liquid chromatography-mass spectrometry (LC-MS). To obtain insights into their lipophilicity, their distribution coefficients between n -octanol/PBS were determined. Both complexes showed affinity mainly for the organic phase, presenting positive log P values. Also, their stability was confirmed over 48 h in different media ( i.e. , DMSO, PBS and cell culture medium) via HPLC, UV-Vis and 31 P{ 1 H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1 , which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer.

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Design, Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage, Cell Cycle Arrest and Apoptosis Induction

Novel Polypyridyl Ruthenium Complexes Acting As High Affinity DNA Intercalators, Potent Transcription Inhibitors and Antitumor Reagents.

Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents

Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines

Chiral Ruthenium(Ii) Polypyridyl Complexes: Stabilization of G-Quadruplex Dna, Inhibition of Telomerase Activity and Cellular Uptake

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives Induce Cancer Cell Apoptosis by Triggering Dna Damage-Mediated P53 Phosphorylation

Synthesis, Characterization and Biological Evaluation of Labile Intercalative Ruthenium(ii) Complexes for Anticancer Drug Screening.

Rational Design of Ruthenium Complexes Containing 2,6‐bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing P53 Activation

Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents.

Discovery Of A Dual-Targeting Organometallic Ruthenium Complex With High Activity Inducing Early Stage Apoptosis Of Cancer Cells

Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity Through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.

Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors